Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Moschini

Showing results (31-40 of 560) with videos related to

Pageof 56
Sort By:
The Journal of Urology|February 8, 2024
Letter: Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS)Francesco Montorsi, Marco Moschini, Giorgio Gandaglia, et al.
Current Opinion in Urology|March 13, 2018
GreenLight Laser for benign prostatic hyperplasiaLivio Mordasini, Marco Moschini, Agostino Mattei, et al.
Minerva Urology and Nephrology|February 11, 2022
Robot-assisted radical cystectomy: towards a future of sexual-sparing surgery?Andrea Gallioli, Benjamin Pradere, Simone Albisinni, et al.
European Urology|March 26, 2023
Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II StudyMarco Moschini, Andrea Salonia, Alberto Briganti, et al.
Current Opinion in Urology|June 5, 2016
Lymph node dissection for renal cell carcinoma: what are we missing?Marco Moschini, Paolo Dell'Oglio, Alessandro Larcher, et al.
European Urology|May 4, 2025
Re: Douglas M. Dahl, Joseph P. Rodgers, William U. Shipley, et al. Bladder-preserving Trimodality Treatment for High-grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol 2024;42:4095-102Paolo Zaurito, Marco Moschini, Alberto Briganti, et al.
European Urology Focus|September 25, 2023
Re: Jakob Klemm, Michael Rink, Markus von Deimling, et al. Time-to-complication Patterns After Radical Cystectomy: A Secondary Analysis of a 30-day Morbidity Assessment Using the European Association of Urology Quality Criteria for Standardized Reporting. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.06.005Francesco Montorsi, Marco Moschini, Giorgio Gandaglia, et al.
BJU International|July 29, 2025
Response to Hof et al.: spurious associations between BCG instillations and outcomes in non-muscle-invasive bladder cancerMattia Longoni, Pietro Scilipoti, Paolo Zaurito, et al.
European Urology|May 20, 2026
Re: Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, et al. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med 2026;394:1257-1269Marco Moschini, Pietro Scilipoti, Mattia Longoni, et al.
Translational Andrology and Urology|October 28, 2016
How to optimally manage elderly bladder cancer patients?Francesco Soria, Marco Moschini, Stephan Korn, et al.
Pageof 56

Showing results (31-40 of 560) with videos related to

Sort By:
Pageof 56
The Journal of Urology|February 8, 2024
Letter: Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS)Francesco Montorsi, Marco Moschini, Giorgio Gandaglia, et al.
Current Opinion in Urology|March 13, 2018
GreenLight Laser for benign prostatic hyperplasiaLivio Mordasini, Marco Moschini, Agostino Mattei, et al.
Minerva Urology and Nephrology|February 11, 2022
Robot-assisted radical cystectomy: towards a future of sexual-sparing surgery?Andrea Gallioli, Benjamin Pradere, Simone Albisinni, et al.
European Urology|March 26, 2023
Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II StudyMarco Moschini, Andrea Salonia, Alberto Briganti, et al.
Current Opinion in Urology|June 5, 2016
Lymph node dissection for renal cell carcinoma: what are we missing?Marco Moschini, Paolo Dell'Oglio, Alessandro Larcher, et al.
European Urology|May 4, 2025
Re: Douglas M. Dahl, Joseph P. Rodgers, William U. Shipley, et al. Bladder-preserving Trimodality Treatment for High-grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol 2024;42:4095-102Paolo Zaurito, Marco Moschini, Alberto Briganti, et al.
European Urology Focus|September 25, 2023
Re: Jakob Klemm, Michael Rink, Markus von Deimling, et al. Time-to-complication Patterns After Radical Cystectomy: A Secondary Analysis of a 30-day Morbidity Assessment Using the European Association of Urology Quality Criteria for Standardized Reporting. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.06.005Francesco Montorsi, Marco Moschini, Giorgio Gandaglia, et al.
BJU International|July 29, 2025
Response to Hof et al.: spurious associations between BCG instillations and outcomes in non-muscle-invasive bladder cancerMattia Longoni, Pietro Scilipoti, Paolo Zaurito, et al.
European Urology|May 20, 2026
Re: Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, et al. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med 2026;394:1257-1269Marco Moschini, Pietro Scilipoti, Mattia Longoni, et al.
Translational Andrology and Urology|October 28, 2016
How to optimally manage elderly bladder cancer patients?Francesco Soria, Marco Moschini, Stephan Korn, et al.
Pageof 56